A molecule has been found to significantly increase the effect of Tamoxifen, a common breast cancer treatment.
Compugen Ltd. (Nasdaq: CGEN; TASE: CGEN) has begun planning for a proof of concept human trial for breast cancer therapy in 2009 for its CGEN-50001 molecule, a known central nervous system drug. Test-tube and animal studies showed that CGEN-50001 significantly increased the effect of Tamoxifen, a common breast cancer treatment. Compugen’s New Indications Discovery Platform had earlier predicted this affect and the company has filed a patent for this usage
CGEN-50001 is a small molecule drug which has been used in the clinic for many years for central nervous system disorders and it has a well established safety profile.
Compugen VP R&D Dr. Yossi Cohen said, “Breast cancer is by far the most common cancer amongst women and therefore has been the target of extensive research for many years. The idea that an existing drug now used for completely unrelated medical conditions might prove of significant benefit for some types or stages of breast cancer is of course extremely exciting."
Published by Globes [online], Israel business news - www.globes-online.com - on July 16, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008